FY2025 EPS Estimates for Sanofi Lifted by Leerink Partnrs

Key Points

• Leerink Partners has raised its FY2025 EPS estimate for Sanofi to $4.28 per share, slightly up from the previous estimate of $4.27.
• Sanofi's recent quarterly earnings report showed an EPS of $0.90, missing estimates of $0.96, while revenues exceeded expectations at $11.34 billion.
• Several major investment firms, including Morgan Stanley and Deutsche Bank, have recently upgraded their ratings on Sanofi, reflecting a generally optimistic outlook for the company's stock.

Sanofi (NASDAQ:SNY - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2025 EPS estimates for Sanofi in a research note issued to investors on Tuesday, October 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn $4.28 per share for the year, up from their prior estimate of $4.27. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's Q4 2025 earnings at $0.83 EPS, FY2026 earnings at $4.70 EPS, FY2027 earnings at $4.90 EPS, FY2028 earnings at $5.21 EPS and FY2029 earnings at $5.67 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company's revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the company posted $1.73 EPS.

SNY has been the subject of a number of other research reports. Morgan Stanley upgraded shares of Sanofi from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $62.67.

Sanofi Trading Up 0.0%

Shares of Sanofi stock opened at $48.82 on Friday. The firm has a 50-day simple moving average of $48.25 and a two-hundred day simple moving average of $49.87. The company has a market cap of $119.88 billion, a P/E ratio of 11.74, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Institutional Trading of Sanofi

Hedge funds have recently made changes to their positions in the company. Accent Capital Management LLC purchased a new stake in shares of Sanofi in the 1st quarter valued at approximately $29,000. Eastern Bank grew its stake in shares of Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after buying an additional 300 shares during the period. Ameritas Advisory Services LLC purchased a new stake in shares of Sanofi in the 2nd quarter valued at approximately $28,000. Golden State Wealth Management LLC grew its stake in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after buying an additional 545 shares during the period. Finally, Banque Transatlantique SA purchased a new stake in shares of Sanofi in the 1st quarter valued at approximately $33,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.